(Q37483162)

English

A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments

scientific article published on June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments (English)

1 reference

Europe PubMed Central

20 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Giulio Rossi

1

1 reference

Europe PubMed Central

20 August 2017

Giulio Rossi

2

1 reference

Europe PubMed Central

20 August 2017

Giuseppe Pelosi

3

1 reference

Europe PubMed Central

20 August 2017

Paolo Graziano

4

1 reference

Europe PubMed Central

20 August 2017

Mattia Barbareschi

5

1 reference

Europe PubMed Central

20 August 2017

Mauro Papotti

6

1 reference

Europe PubMed Central

20 August 2017

publication date

1 June 2009

1 reference

Europe PubMed Central

20 August 2017

International Journal of Surgical Pathology

1 reference

Europe PubMed Central

20 August 2017

17

1 reference

Europe PubMed Central

20 August 2017

206-218

1 reference

Europe PubMed Central

20 August 2017

3

1 reference

Europe PubMed Central

20 August 2017

Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Bronchioloalveolar carcinoma: the case for two diseases

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Keratin expression in human tissues and neoplasms

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

34betaE12 Cytokeratin Immunodetection in the Differential Diagnosis of Small Cell Tumors of Lung

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

p63 immunostaining in destained bronchoscopic cytological specimens

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Subcellular localization of immunohistochemical signals: knowledge of the ultrastructural or biologic features of the antigens helps predict the signal localization and proper interpretation of immunostains

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Cancer. A bull's eye for targeted lung cancer therapy

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Bevacizumab in non small cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Gene expression profiling of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Personalized medicine and proteomics: lessons from non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

1 reference

https://api.crossref.org/works/10.1177%2F1066896909336178

21 January 2018

Identifiers

10.1177/1066896909336178

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37483162&oldid=2103600911"